Towa Expands Internationally With Esteve’s Pensa
All-Cash €320m Deal Offers Access To Europe And US
Japan’s Towa has struck a deal to acquire the Pensa Investments generics division of Spain’s Esteve in an all-cash transaction worth €320m. The acquisition gives Towa access to the Spanish market as well as subsidiaries in Europe and the US.
You may also be interested in...
Japan’s Towa has completed its €329m deal for the Pensa Investments generics business of Spain’s Esteve.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
Entering new markets, including the US, through partnerships forms a key part of Towa Pharmaceutical’s ‘Proactive’ medium-term business plan. Editor Aidan Fry examines the Japanese generics specialist’s growth strategy.